Proteomics International Laboratories has received a milestone seal of approval for its industrial-scale Perth-based laboratory. The pivotal international certification will support the roll-out of the company’s precise yet simple diagnostic blood tests in Australia.
The internationally recognised ISO 15189 medical testing accreditation validates the company’s ability to deliver accurate and reliable clinical results, supporting the commercialisation of Proteomics’ cutting-edge “traffic light” system diagnostic portfolio.
Proteomics International Laboratories has achieved certification for its Perth lab, which will provide world-class test results for precision medicine.
That portfolio is expanding rapidly in four significant diagnostic fields. Proteomics recently launched its PromarkerD test for diabetic kidney disease and PromarkerEso test for oesophageal cancer.
After a rigorous audit of its Perth-based lab facilities, systems and processes, the precision medical technology company got the regulatory nod. The latest certification builds on its existing list of international medical accreditations, placing the company at the head of the pack of the world’s leading proteomics and protein-based testing services.
‘The clinical certification supports our strategic growth trajectory as we advance the commercialisation of our first-in-class diagnostic tests for diabetic kidney disease, oesophageal cancer and endometriosis.’
Proteomics International managing director Dr Richard Lipscombe
The development positions Proteomics to offer both its in-house tests and emerging third-party specialist pathology tests, opening potential new revenue streams as precision medicine gains traction globally.
The company’s PromarkerD and PromarkerEso, along with its PromarkerEndo test for endometriosis, are powered by its Promarker platform, which detects protein biomarkers in blood to deliver a universal “traffic light” risk score for the diseases. The company holds a Japanese patent for Promarker Endo, which has helped it progress towards global commercialisation.
Proteomics International managing director Dr Richard Lipscombe said: “The clinical certification supports our strategic growth trajectory as we advance the commercialisation of our first-in-class diagnostic tests for diabetic kidney disease, oesophageal cancer and endometriosis. This certification also cements Proteomics International’s position as a leading innovator in precision diagnostics and provides a platform for us to offer more specialist pathology testing in future.”
Proteomics’ latest certification enhances its capacity to scale its diagnostic offerings, backing high-quality testing for clinical and research applications. The company says it will also strengthen its ability to collaborate with global partners, leveraging its state-of-the-art Perth facility to drive innovation and expand its already extensive supply.
